FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

In the long battle to create an effective HIV vaccine, scientists have made a major leap forward. A new study shows that a ...